keyword
MENU ▼
Read by QxMD icon Read
search

Paclitaxel

keyword
https://www.readbyqxmd.com/read/29054689/breast-cancer-survivorship-care-variations-between-adjuvant-chemotherapy-regimens
#1
Alexis D Leal, Holly Van Houten, Lindsey Sangaralingham, Rachel A Freedman, Ahmedin Jemal, Heather B Neuman, Tufia C Haddad, Robert W Mutter, Theresa H M Keegan, Sarah S Mougalian, Charles L Loprinzi, Cary P Gross, Nilay Shah, Kathryn J Ruddy
BACKGROUND: Treatment-related toxicity can vary substantially between chemotherapy regimens. In this study we evaluated the frequency of outpatient office visits among a cohort of early stage breast cancer survivors after completion of 4 different adjuvant chemotherapy regimens to better understand how differences in toxicities between regimens might affect health care use. MATERIALS AND METHODS: We analyzed administrative claims data from a US commercial insurance database (OptumLabs) to identify women who received adjuvant doxorubicin/cyclophosphamide (AC), AC followed or preceded by docetaxel or paclitaxel (AC-T), AC concurrent with docetaxel or paclitaxel (TAC), or docetaxel/cyclophosphamide (TC) between 2008 and 2014...
September 22, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29054369/exosome-is-a-mechanism-of-intercellular-drug-transfer-application-of-quantitative-pharmacology
#2
Jin Wang, Bertrand Z Yeung, Minjian Cui, Cody J Peer, Ze Lu, William D Figg, M Guillaume Wientjes, Sukyung Woo, Jessie L-S Au
PURPOSE: Exosomes are small membrane vesicles (30-100nm in diameter) secreted by cells into extracellular space. The present study evaluated the effect of chemotherapeutic agents on exosome production and/or release, and quantified the contribution of exosomes to intercellular drug transfer and pharmacodynamics. METHODS: Human cancer cells (breast MCF7, breast-to-lung metastatic LM2, ovarian A2780 and OVCAR4) were treated with paclitaxel (PTX, 2-1000nM) or doxorubicin (DOX, 20-1000nM) for 24-48h...
October 17, 2017: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/29053265/step-economical-photoassisted-diversity-oriented-synthesis-sustaining-cascade-photoreactions-in-oxalyl-anilides-to-access-complex-polyheterocyclic-molecular-architectures
#3
Dmitry M Kuznetsov, Andrei G Kutateladze
Atom- and step-economy in photoassisted DOS is achieved with a versatile oxalyl linker offering rapid access to complex alkaloid mimics in very few experimentally simple steps: (i) it allows for fast tethering of the photoactive core to the unsaturated pendants, especially im-portant in the case of (hetero)aromatic amines - essentially a one pot reaction with no isolation of intermediates; (ii) the α-dicarbonyl tether acts as a chromophore enhancer, extending the conjugation chain and facilitating the 'harvest' of the lower energy photons for the primary and secondary photoreactions, (iii) it enhances the quantum yield of intersystem crossing (ISC), i...
October 20, 2017: Journal of the American Chemical Society
https://www.readbyqxmd.com/read/29050631/drug-coated-balloon-treatment-for-femoropopliteal-artery-disease-the-in-pact-global-study-de-novo-in-stent-restenosis-imaging%C3%A2-cohort
#4
Marianne Brodmann, Koen Keirse, Dierk Scheinert, Lubomir Spak, Michael R Jaff, Randy Schmahl, Pei Li, Thomas Zeller
OBJECTIVES: This study sought to evaluate the safety and effectiveness of a paclitaxel-coated drug-coated balloon (DCB) for the treatment of patients with de novo in-stent restenosis (ISR). BACKGROUND: Treatment of patients with ISR remains a challenge. Current strategies are plagued by high rates of recurrent restenosis and need for reintervention. The best intervention for ISR remains to be elucidated. METHODS: The IN.PACT Global study is an independently adjudicated multicenter, prospective, single-arm study that enrolled 1,535 subjects with symptomatic atherosclerotic disease of the superficial femoral and/or popliteal arteries, including de novo ISR lesions...
October 23, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/29050332/survival-outcomes-based-on-systemic-agent-used-concurrently-with-radiation-in-human-papillomavirus-associated-oropharyngeal-cancer
#5
Vikas Mehta, Tara Moore-Medlin, Jose M Flores, Xiaohui Ma, Oleksandr Ekshyyan, Cherie-Ann O Nathan
PURPOSE: To investigate survival outcomes of patients treated with concurrent cetuximab and radiotherapy for primary management of both HPV positive and negative OPSCC, and compare the results to traditional platinum-based therapy. We hypothesize that the use of cetuximab in the HPV positive OPSCC patients will result in inferior survival based on tumor biological differences. STUDY DESIGN: A single institution retrospective analysis of 304 patients. The primary outcomes of interest were 1) overall survival and 2) relapse free survival...
September 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29049199/paclitaxel-as-third-line-chemotherapy-for-small-cell-lung-cancer-failing-both-etoposide-and-camptothecin-based-chemotherapy
#6
Se Hyun Kim, Mi-Jung Kim, Yu Jung Kim, Hyun Chang, Jin Won Kim, Jeong-Ok Lee, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee
Paclitaxel has been shown to have clinical activity in the treatment of small cell lung cancer (SCLC). However, its role as third-line chemotherapy for SCLC after both etoposide- and camptothecin-based regimens has not been clarified.All patients with refractory SCLC who were treated with paclitaxel-based regimen as third-line chemotherapy between 2005 and 2011 in Seoul National University Bundang Hospital were reviewed retrospectively. Forty patients previously treated with both etoposide- and camptothecin-based chemotherapy were included...
October 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29049188/incidence-of-venous-thromboembolism-following-the-neoadjuvant-chemotherapy-regimen-for-epithelial-type-of-ovarian-cancer
#7
Devendra Manik Chavan, Zhen Huang, Kun Song, Leela Rani Haricharan Parimi, Xing Sheng Yang, Xiangning Zhang, Peishu Liu, Jie Jiang, Youzhong Zhang, Beihua Kong, Li Li
This study aims to analyze the risk of venous thromboembolism (VTE) in patients receiving neoadjuvant chemotherapy (NACT) for epithelial ovarian cancer (EOC).A retrospective audit was conducted examining 147 patients treated for EOC. Surgical treatment with curative intent, with or without NACT and adjuvant chemotherapy, is the treatment approach, which was modified according to the patient's condition. The incidence of VTE with the most commonly used chemotherapy regimen, carboplatin, cisplatin, paclitaxel, docetaxel, and others were evaluated...
October 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29048649/paclitaxel-mediated-human-aryl-hydrocarbon-receptor-mrna-translation-by-an-internal-ribosomal-entry-site-dependent-mechanism
#8
Wen-Qing Gao, Jing Ma, Liu-Liu Sun, Qi Li, Rui-Yu Zhu, Jian Jin
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that is best known in mediating the toxicities of dioxins and dioxin-like compounds. AHR is activated by a variety of endogenous ligands and participating in tumor development. Thus, it will provide a new approach for cancer prevention and treatment to study the translation mechanism of AHR in tumor cells. In this study, we show that the 5'-untranslated region (UTR) of AHR mRNA contains an internal ribosome entry site (IRES). After mapping the entire AHR 5'-UTR, we determined that the full-length 5'-UTR is indispensable for the highest IRES activity...
September 18, 2017: Oncology Reports
https://www.readbyqxmd.com/read/29048634/-retracted-efficacy-of-dual-functional-liposomes-containing-paclitaxel-for-treatment-of-lung-cancer
#9
Rong-Hua Wang, Hong-Mei Cao, Zhi-Ju Tian, Bo Jin, Qing Wang, Hong Ma, Jing Wu
Following the publication of this article, the authors find that they are not able to reproduce the results presented in this paper. Consequently, the authors have decided to retract this paper from publication. All of the authors agree to this retraction. The authors sincerely regret this decision, and apologize to the Editor and to the readership of the Journal for any inconvenience caused. [the original article was published in Oncology Reports 33: 783-791, 2015; DOI: 10.3892/or.2014.3644].
September 26, 2017: Oncology Reports
https://www.readbyqxmd.com/read/29048400/cd10-aldh-cells-are-the-sole-cisplatin-resistant-component-of-a-novel-ovarian-cancer-stem-cell-hierarchy
#10
Brendan Ffrench, Claudia Gasch, Karsten Hokamp, Cathy Spillane, Gordon Blackshields, Thamir Mahmoud Mahgoub, Mark Bates, Louise Kehoe, Aoibhinn Mooney, Ronan Doyle, Brendan Doyle, Dearbhaile O'Donnell, Noreen Gleeson, Bryan T Hennessy, Britta Stordal, Ciaran O'Riain, Helen Lambkin, Sharon O'Toole, John J O'Leary, Michael F Gallagher
It is long established that tumour-initiating cancer stem cells (CSCs) possess chemoresistant properties. However, little is known of the mechanisms involved, particularly with respect to the organisation of CSCs as stem-progenitor-differentiated cell hierarchies. Here we aimed to elucidate the relationship between CSC hierarchies and chemoresistance in an ovarian cancer model. Using a single cell-based approach to CSC discovery and validation, we report a novel, four-component CSC hierarchy based around the markers cluster of differentiation 10 (CD10) and aldehyde dehydrogenase (ALDH)...
October 19, 2017: Cell Death & Disease
https://www.readbyqxmd.com/read/29046799/retrospective-analysis-of-acute-exacerbation-of-interstitial-lung-diseases-with-nanoparticle-albumin-bound-paclitaxel-in-patients-with-advanced-lung-cancer-with-preexisting-interstitial-lung-disease
#11
Yuto Yasuda, Takashi Nomizo, Hiroaki Ozasa, Tomoko Funazo, Takahiro Tsuji, Hironori Yoshida, Yuichi Sakamori, Hiroki Nagai, Tomohiro Handa, Takeshi Kubo, Young Hak Kim
Lung cancer with preexisting interstitial lung disease (ILD) is difficult to treat due to the risk of acute exacerbation of ILD. Nanoparticle albumin-bound (nab-) paclitaxel improves the overall response rate and reduces neuropathy more efficiently compared with conventional solvent-based (sb-) paclitaxel in patients with advanced non-small-cell lung cancer. However, it is not known whether the risk of acute exacerbation of ILD with nab-paclitaxel is higher compared with that with sb-paclitaxel. Advanced lung cancer patients with ILD treated with nab-paclitaxel (n=14) or sb-paclitaxel (n=14) were retrospectively reviewed...
October 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29045554/veliparib-with-temozolomide-or-carboplatin-paclitaxel-versus-placebo-with-carboplatin-paclitaxel-in-patients-with-brca1-2-locally-recurrent-metastatic-breast-cancer-randomized-phase-ii-study
#12
H S Han, V Diéras, M Robson, M Palácová, P K Marcom, A Jager, I Bondarenko, D Citrin, M Campone, M L Telli, S M Domchek, M Friedlander, B Kaufman, J E Garber, Y Shparyk, E Chmielowska, E H Jakobsen, V Kaklamani, W Gradishar, C K Ratajczak, C Nickner, Q Qin, J Qian, S P Shepherd, S J Isakoff, S Puhalla
Background: Homologous recombination defects in BRCA1/2-mutated tumors result in sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors, which interfere with DNA damage repair. Veliparib, a potent PARP inhibitor, enhanced the antitumor activity of platinum agents and temozolomide in early phase clinical trials. This phase II study examined the safety and efficacy of intermittent veliparib with carboplatin/paclitaxel (VCP) or temozolomide (VT) in patients with BRCA1/2-mutated breast cancer...
September 29, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045508/response-to-survival-advantage-for-etoposide-cisplatin-over-paclitaxel-carboplatin-concurrent-chemoradiation-in-patients-with-inoperable-stage-iii-nsclc-a-subgroup-analysis-for-ecog-2-patients-would-be-of-great-interest
#13
N Bi, J Liang, L Wang
No abstract text is available yet for this article.
September 25, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29044971/drug-nanocrystals-for-cancer-therapy
#14
REVIEW
Xiaoqing Miao, Wuwei Yang, Tao Feng, Jing Lin, Peng Huang
Drug nanocrystals (NCs) with fascinating physicochemical properties have attracted great attention in drug delivery. High drug-loading efficiency, great structural stability, steady dissolution, and long circulation time are a few examples of these properties, which makes drug NCs an excellent formulation for efficient cancer therapy. In the last two decades, there are a lot of hydrophobic or lipophilic drugs, such as paclitaxel (PTX), camptothecin (CPT), thymectacin, busulfan, cyclosporin A, 2-devinyl-2-(1-hexyloxyethyl) pyropheophorbide (HPPH), and so on, which have been formulated into drug NCs for cancer therapy...
October 17, 2017: Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology
https://www.readbyqxmd.com/read/29044542/survival-outcome-of-women-with-stage-iv-uterine-carcinosarcoma-who-received-neoadjuvant-chemotherapy-followed-by-surgery
#15
Koji Matsuo, Marian S Johnson, Dwight D Im, Malcolm S Ross, Stephen H Bush, Mayu Yunokawa, Erin A Blake, Tadao Takano, Merieme M Klobocista, Kosei Hasegawa, Yutaka Ueda, Masako Shida, Tsukasa Baba, Shinya Satoh, Takuhei Yokoyama, Hiroko Machida, Yuji Ikeda, Sosuke Adachi, Takahito M Miyake, Keita Iwasaki, Shiori Yanai, Satoshi Takeuchi, Masato Nishimura, Tadayoshi Nagano, Munetaka Takekuma, Mian M K Shahzad, Tanja Pejovic, Kohei Omatsu, Joseph L Kelley, Frederick R Ueland, Lynda D Roman
BACKGROUND AND OBJECTIVES: To examine survival of women with stage IV uterine carcinosarcoma (UCS) who received neoadjuvant chemotherapy followed by hysterectomy. METHODS: This is a nested case-control study within a retrospective cohort of 1192 UCS cases. Women who received neoadjuvant chemotherapy followed by hysterectomy based-surgery for stage IV UCS (n = 26) were compared to those who had primary hysterectomy-based surgery without neoadjuvant chemotherapy for stage IV UCS (n = 120)...
October 16, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29044496/ncctg-n0879-alliance-a-randomized-phase-2-cooperative-group-trial-of-carboplatin-paclitaxel-and-bevacizumab%C3%A2-%C3%A2-%C3%A2-everolimus-for-metastatic-melanoma
#16
Robert R McWilliams, Jacob B Allred, Jessica A Slostad, Rajini Katipamula, Roxana S Dronca, Kandelaria M Rumilla, Lori A Erickson, Alan H Bryce, Richard W Joseph, Lisa A Kottschade, David M King, John M Leitch, Svetomir N Markovic
BACKGROUND: Despite the success of immune checkpoint and targeted therapy, many patients with melanoma ultimately require further treatment. The combination of carboplatin, paclitaxel, and bevacizumab (CPB) has demonstrated promising activity in a single-arm study. In the current study, the authors performed a randomized phase 2 study to confirm efficacy and to determine whether adding everolimus would increase the activity of the combination. METHODS: Through the North Central Cancer Treatment Group, a total of 149 patients with unresectable AJCC 6th edition stage IV melanoma were randomized from May 2010 to May 2014 to either CPB or CPB with everolimus (CPBE)...
October 17, 2017: Cancer
https://www.readbyqxmd.com/read/29044458/patient-reported-quality-of-life-outcomes-after-de-escalated-chemoradiation-for-human-papillomavirus-positive-oropharyngeal-carcinoma-findings-from-a-phase-2-trial
#17
John V Hegde, Narek Shaverdian, Megan E Daly, Carol Felix, Deborah L Wong, Michael H Rosove, Jordan H Garst, Pin-Chieh Wang, Darlene Veruttipong, Shyam Rao, Ruben C Fragoso, Jonathan W Riess, Michael L Steinberg, Allen M Chen
BACKGROUND: The current study represents a subset analysis of quality-of-life (QOL) outcomes among patients treated on a phase 2 trial of de-escalated chemoradiation for human papillomavirus (HPV)-associated oropharyngeal cancer. METHODS: Eligibility included newly diagnosed, (American Joint Committee on Cancer, 7th edition) stage III or IV oropharyngeal squamous cell carcinoma, p16 positivity, age ≥ 18 years, and a Zubrod performance status of 0 to 1. Treatment was induction paclitaxel at a dose of 175 mg/m(2) and carboplatin at an area under the curve of 6 for 2 cycles followed by response-adapted, dose-reduced radiation of 54 Gy or 60 Gy with weekly concurrent paclitaxel at a dose of 30 mg/m(2) ...
October 17, 2017: Cancer
https://www.readbyqxmd.com/read/29044153/tripalmitin-nanoparticle-formulations-significantly-enhance-paclitaxel-antitumor-activity-against-breast-and-lung-cancer-cells-in-vitro
#18
María Carmen Leiva, Raúl Ortiz, Rafael Contreras-Cáceres, Gloria Perazzoli, Iryna Mayevych, Juan Manuel López-Romero, Francisco Sarabia, Jose Manuel Baeyens, Consolación Melguizo, Jose Prados
Paclitaxel (PTX) is one of the drugs of choice in the treatment of breast and lung cancer. However, its severe side effects, including mielosuppression, cardiotoxicity and neurotoxicity, frequently cause treatment to be discontinued. Solid lipid nanoparticles (NPs) of glyceril tripalmitate (tripalmitin) loaded with PTX (Tripalm-NPs-PTX) including modifications by the addition of hexa(ethylene glycol), β-cyclodextrin and macelignan were developed. All NPs-PTX formulations displayed excellent hemocompatibility and significantly enhanced PTX antitumor activity in human breast (MCF7, MDAMB231, SKBR3 and T47D) and lung (A549, NCI-H520 and NCI-H460) cancer cells...
October 18, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29044008/analysis-of-the-effect-of-paclitaxel-eluting-stents-and-paclitaxel-eluting-balloon-in-the-treatment-of-in-stent-restenosis
#19
Jiangtao Cheng, Chuanyu Gao, Yuhao Liu, Zhongmin Wang, Xiaohui Zheng, Datun Qi
To compare and analyze the effect and the safety of the paclitaxel-eluting stents and paclitaxel-eluting balloon in the treatment for in-stent rest enosis. 120 cases, who had been undergone percutaneous coronary intervention (PCI) in the Department of Cardiology of Henan Provincial People's Hospital from January 2012 to January 2014 were selected. All the patients were randomly treated with paclitaxel-eluting balloon or paclitaxel-eluting stents. The former were divided into different groups that named group A and the later group B...
July 2017: Pakistan Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29043926/efficient-induction-of-apoptosis-in-cancer-cells-by-paclitaxel-loaded-selenium-nanoparticles
#20
Anil Parsram Bidkar, Pallab Sanpui, Siddhartha Sankar Ghosh
AIM: To develop selenium nanoparticles (SeNPs)-based delivery systems for paclitaxel (PTX) and assess their antiproliferative efficacy against cancer cells in vitro with potential mechanistic insight. METHODS: Pluronic F-127 stabilized SeNPs were prepared and characterized. Effects of PTX-loaded SeNPs on lung (A549), breast (MCF7), cervical (HeLa) and colon (HT29) cancer cells were studied by viability assay complemented with flow-cytometric analyses of cell cycle, apoptosis, mitochondrial membrane potential, intracellular reactive oxygen species and caspase activity...
October 18, 2017: Nanomedicine
keyword
keyword
35091
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"